Pharmaceutical group Adcock Ingram has managed to turn its rest of Africa operations profitable, contributing to a tripling of after-tax profit in the year to end-June. Adcock Ingram grew overall revenue by 7% to R5.96bn and after-tax profit was up 213% to R561m in the year to end-June. The group declared a final dividend of 76c, taking its total for the year to R1.39, a 34% increase on the prior year’s R1.04. Over-the-counter (OTC) medicines are Adcock Ingram’s second-biggest contributor to revenue but biggest contributor profit. Its OTC division grew revenue by 11% to R1.8bn, contributing 31% of group revenue. Adcock Ingram says the process of re-engineering its business has borne fruit and allowed it to claw back profit in a tough operating environment. The pharmaceutical company said on Friday the shake-up of the leadership team had also restored its trusted reputation in SA. A new management was installed by Bidvest in 2014 after the group acquired a majority interest in the fi...

BL Premium

This article is reserved for our subscribers.

A subscription helps you enjoy the best of our business content every day along with benefits such as exclusive Financial Times articles, ProfileData financial data, and digital access to the Sunday Times and Sunday Times Daily.

Already subscribed? Simply sign in below.

Questions or problems? Email or call 0860 52 52 00. Got a subscription voucher? Redeem it now